Verona Pharma is scheduled to hold an Investor Update event in New York City on October 18, 2023, from 8:00 AM to 10:00 AM ET. During this event, members of Verona’s senior management team and key opinion leader Cedric “Jamie” Rutland, MD, FCCP, Medical Director & CEO of West Coast Lung, will discuss the treatment paradigm for chronic obstructive pulmonary disease (COPD) and the company’s preparations for the potential launch of ensifentrine in the US, pending approval.
In September 2023, the US Food and Drug Administration (FDA) accepted Verona Pharma’s New Drug Application (NDA) for ensifentrine, a treatment for COPD maintenance. The FDA has set a target action date of June 26, 2024, for the NDA and is currently not planning an advisory committee meeting for application review.
The event will be available via a live audio webcast on the Investors page of Verona Pharma’s website. Please note that in-person attendance for the event is by invitation only.
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic respiratory diseases with significant unmet medical needs. Their lead product candidate, ensifentrine, is a potential first-in-class non-steroidal therapy for respiratory diseases that combines bronchodilator and anti-inflammatory activities in one molecule.
Ensifentrine has shown promising results in Phase 3 clinical trials for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with significant improvements in lung function and a reduction in COPD exacerbations.
The company’s goal is to provide effective treatments for patients with chronic respiratory diseases, including COPD, asthma, and cystic fibrosis, by advancing the development and commercialization of innovative therapies like ensifentrine.